Biologic therapeutic - Traverse Biotech
Latest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator Unknown
- Developer Traverse Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 20 Sep 2023 Early research in Cancer in USA (unspecified route), prior to September 2023 (Traverse Biotech pipeline, September 2023)